Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study - 19/06/24
Doi : 10.1016/j.jaad.2024.03.019
Kyle C. Lauck, MD a, ⁎ 
, Allison Limmer, MD a, Peyton Harris, BS b, Dario Kivelevitch, MD a, c
, Allison Limmer, MD a, Peyton Harris, BS b, Dario Kivelevitch, MD a, c a Division of Dermatology, Baylor University Medical Center, Dallas, Texas
b Texas A&M School of Medicine, Dallas, Texas
c Clarity Dermatology, Dallas, Texas
∗Correspondence to: Kyle C. Lauck, MD, Division of Dermatology, Baylor University Medical Center, Roberts Hospital Suite 613, 3501 Junius St, Dallas, TX 75246Division of DermatologyBaylor University Medical CenterRoberts Hospital Suite 6133501 Junius StDallasTX75246
Key words : 5-alpha-reductase inhibitor, androgenetic alopecia, dutasteride, epidemiology, erectile dysfunction, finasteride, pharmacology, sexual dysfunction
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Data accessible via TriNetX only contains anonymized information as per the deidentification standard defined by the US Health Insurance Portability and Accountability Act (HIPAA) in section §164,514(a). Given this study used only deidentified data and did not involve individually identifiable patient data, this study was exempt from institutional review board approval. |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 91 - N° 1
P. 163-166 - juillet 2024 Retour au numéro
Article précédent
- Correlation of clinical and trichoscopy features with the degree of histologic inflammation in lichen planopilaris and frontal fibrosing alopecia in a cross-sectional study
- Carolina Oliveira Costa Fechine, Neusa Yurico Sakai Valente, Ricardo Romiti, Maryanne Makredes Senna
- Dermatologic findings associated with semaglutide use: A scoping review
- Megan M. Tran, Fatima N. Mirza, Adrian C. Lee, Hayley S. Goldbach, Tiffany J. Libby, Oliver J. Wisco
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?